{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T01:21:46Z","timestamp":1793496106102,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neurol.2026.05.002","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T11:29:19Z","timestamp":1781695759000},"page":"632-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?"],"prefix":"10.1016","volume":"182","author":[{"given":"A.","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Derost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Debilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Rieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Durif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neurol.2026.05.002_bib0140","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/brain\/awaa181","article-title":"Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa","volume":"143","author":"Cilia","year":"2020","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neurol.2026.05.002_bib0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/WNF.0000000000000082","article-title":"Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses","volume":"38","author":"Bhidayasiri","year":"2015","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3233\/JPD-230372","article-title":"Effectiveness of continuous dopaminergic therapies in Parkinson's disease: a review of L-DOPA pharmacokinetics\/pharmacodynamics","volume":"14","author":"Demailly","year":"2024","journal-title":"J Parkinsons Dis"},{"issue":"9","key":"10.1016\/j.neurol.2026.05.002_bib0155","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s10072-019-03972-7","article-title":"Correction to: continuous subcutaneous apomorphine infusion in Parkinson's disease: causes of discontinuation and subsequent treatment strategies","volume":"40","author":"Olivola","year":"2019","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0160","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/1877718X251344896","article-title":"Twenty-five-year experience with apomorphine pump in Parkinson's disease: a real-life long-term retrospective tolerance study","volume":"15","author":"Potel","year":"2025","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2026.05.002_bib0165","doi-asserted-by":"crossref","first-page":"105859","DOI":"10.1016\/j.parkreldis.2023.105859","article-title":"Discontinuation rate and long-term adverse events path of apomorphine infusion in advanced Parkinson's disease patients","volume":"116","author":"Camgrand","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.002_bib0170","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41531-021-00194-7","article-title":"Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study","volume":"7","author":"Meira","year":"2021","journal-title":"NPJ Parkinsons Dis"},{"issue":"6","key":"10.1016\/j.neurol.2026.05.002_bib0175","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/mds.10281","article-title":"Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients","volume":"17","author":"Manson","year":"2002","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.002_bib0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.26444\/aaem\/99699","article-title":"Continuous subcutaneous apomorphine monotherapy in Parkinson's disease","volume":"26","author":"Papu\u0107","year":"2019","journal-title":"Ann Agric Environ Med"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0190","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s12325-022-02072-x","article-title":"Long-term persistence and monotherapy with device-aided therapies: a retrospective analysis of an Israeli cohort of patients with advanced Parkinson's disease","volume":"39","author":"Thaler","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2026.05.002_bib0195","doi-asserted-by":"crossref","first-page":"107905","DOI":"10.1016\/j.parkreldis.2025.107905","article-title":"Continuous subcutaneous infusion therapies in Parkinson's disease: evidence of efficacy and safety","volume":"139","author":"Katzenschlager","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2026.05.002_bib0200","doi-asserted-by":"crossref","first-page":"107866","DOI":"10.1016\/j.parkreldis.2025.107866","article-title":"A delphi consensus statement about French practical management of continuous apomorphine infusion in patients with Parkinson's disease and motor fluctuations","volume":"139","author":"Ory Magne","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"10.1016\/j.neurol.2026.05.002_bib0205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.14802\/jmd.23057","article-title":"Apomorphine monotherapy for Parkinson's disease: a neglected option?","volume":"16","author":"Desjardins","year":"2023","journal-title":"J Mov Disord"},{"issue":"12","key":"10.1016\/j.neurol.2026.05.002_bib0210","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.neurol.2026.05.002_bib0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0220","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s00415-017-8477-0","article-title":"Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients","volume":"264","author":"Sesar","year":"2017","journal-title":"J Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2026.05.002_bib0225","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-004-0547-4","article-title":"A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease","volume":"251","author":"Tyne","year":"2004","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2026.05.002_bib0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2015.11.013","article-title":"Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients","volume":"23","author":"Borgemeester","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"10.1016\/j.neurol.2026.05.002_bib0235","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","article-title":"Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson's disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study","volume":"21","author":"De Cock","year":"2022","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.neurol.2026.05.002_bib0240","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/mdc3.13799","article-title":"Night-time apomorphine infusion: who are the best candidates?","volume":"10","author":"Cochen De Cock","year":"2023","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"10.1016\/j.neurol.2026.05.002_bib0245","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/mds.22063","article-title":"Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study","volume":"23","author":"Garc\u00eda Ruiz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2026.05.002_bib0250","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parkreldis.2016.04.023","article-title":"Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence","volume":"27","author":"Borgemeester","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.002_bib0255","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mdc3.70240","article-title":"Subcutaneous apomorphine infusion initiation is associated with impulse control disorder attenuation in advanced Parkinson's disease patients: insights from the French NS-Park cohort","volume":"13","author":"Desjardins","year":"2026","journal-title":"Mov Disord Clin Pract"},{"issue":"s1","key":"10.1016\/j.neurol.2026.05.002_bib0260","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.3233\/JPD-181476","article-title":"Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease","volume":"8","author":"van Wamelen","year":"2018","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"10.1016\/j.neurol.2026.05.002_bib0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-014-0220-0","article-title":"Medication adherence in patients with Parkinson's disease","volume":"29","author":"Malek","year":"2015","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.neurol.2026.05.002_bib0270","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mds.22112","article-title":"Adherence to antiparkinson medication in a multicenter European study","volume":"24","author":"Grosset","year":"2009","journal-title":"Mov Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726005527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:52:13Z","timestamp":1786542733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726005527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0035378726005527"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.002","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuous subcutaneous perfusion of apomorphine in Parkinson's disease: Towards monotherapy?","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}